Table of Contents
A patent portfolio analysis Basel life-sciences teams rely on has to be built for the densest big-pharma patent cluster on earth, and for a jurisdiction that sits deliberately outside the European Union’s unitary patent system. Basel is the global headquarters of both Roche and Novartis, two of the world’s largest pharmaceutical patent holders, and the hub of a tri-national research region that reaches into France and Germany. Yet a patent enforced here is a Swiss national right, granted by an office that does not test it for novelty, and defended before a single specialist court in St. Gallen. Both facts change how a portfolio has to be read, valued and pruned.
Why patent portfolio analysis Basel starts with the world’s densest pharma cluster
Begin with the industry, because in Basel it is the portfolio. The city is the number-one life-sciences location in Europe, home to the global headquarters of Roche and Novartis and the working base of Bayer, Boehringer Ingelheim, Johnson & Johnson and Moderna. Around them sit at least fourteen pharma companies, some eighty-five biotech firms and dozens of medtech businesses, all filing and licensing patents at scale.
That concentration changes what a portfolio review is for. The typical Basel estate is not a scatter of unrelated inventions but a dense web of composition, formulation, manufacturing, dosage-regimen and method-of-treatment patents, often clustered around a single blockbuster molecule and its lifecycle. The value sits in how those families interlock and how long they can hold a market, not in a raw patent count.
A rigorous patent portfolio analysis Basel companies commission therefore maps families to products, products to markets, and each patent to the expiry that actually governs exclusivity. It separates the patents doing real commercial work from the maintenance-fee dead weight, and it flags where a competitor’s own filings are closing in on your space.
Switzerland outside the UPC: what national validation really means
The single fact that most surprises out-of-region counsel is jurisdictional. Switzerland is not in the European Union, not in the EU’s Unified Patent Court, and not covered by the unitary patent. A European patent granted by the EPO does not automatically reach Switzerland the way it now can across the participating EU states.
Instead, a European patent must be validated nationally in Switzerland after grant, where it becomes an ordinary Swiss patent administered by the Swiss Federal Institute of Intellectual Property (IPI, or IGE). Switzerland and Liechtenstein form a single unitary protection territory under their 1978 Patent Treaty, so one validation covers both countries at once and cannot be split between them.
For portfolio work this has hard consequences. A Swiss patent cannot be centrally revoked at the UPC, so it survives as a standalone asset even when a matching unitary patent is knocked out across the EU. That makes the Swiss designation a strategic backstop worth analysing on its own terms, with its own renewal budget, its own validity risk, and its own enforcement path, rather than lumping it into a pan-European line item.
The IPI registration grant and why unexamined patents change the read
How a patent was granted shapes how much it is worth, and Swiss national grants are unusual. Under current practice the IPI grants a national patent without examining it for novelty or inventive step. The office checks formal and legal requirements, but the substantive question of whether the invention is actually new is left open, so a Swiss patent is granted “without guarantee” and can be declared invalid later if challenged.
That is a double-edged asset in a portfolio. A registration-style grant is fast and cheap to obtain, but its presumption of validity is thinner than a fully examined European or U.S. patent, and its strength has never been tested against the prior art. A portfolio review has to price that uncertainty rather than assume the grant certificate settles it.
We therefore treat Swiss national patents as claims that still need a validity read, pairing the portfolio map with targeted prior art & litigation search on the assets that carry real commercial weight. Note too that the Swiss Patent Act reform taking effect on 1 January 2027 will let applicants request full substantive examination, so newer filings may soon carry a different validity profile from the legacy estate.
SPCs, paediatric extensions and patent-term lifecycle management
In a Basel pharma portfolio, the most valuable years of exclusivity often come after the basic patent expires, so a review that stops at the twenty-year term misses the point. Switzerland grants supplementary protection certificates (SPCs) that extend protection for a patented active ingredient by up to five years, running from the moment the twenty-year patent term ends, to compensate for the time lost to Swissmedic marketing approval.
There is a further layer for medicines studied in children. Since 1 January 2019, Switzerland has offered a six-month paediatric extension of an SPC, and even stand-alone paediatric certificates for patents that never had an SPC at all. For a drug with a long approval history, these instruments can decide whether a franchise holds its market for one more year or loses it to generics early.
A patent portfolio analysis Basel sponsors need has to model each product’s real expiry cliff: basic patent, SPC, paediatric extension and any secondary patents, molecule by molecule. We map the IPI’s SPC register entries against product approvals to show exactly when exclusivity ends and where a lifecycle-extension filing is still available before the window closes.
Second-medical-use and secondary claims in a portfolio review
Basel portfolios lean heavily on secondary patents, and second-medical-use claims are the classic example. When a known compound is found to treat a new disease, a fresh patent can protect that specific therapeutic use even though the molecule itself is old, extending commercial exclusivity well beyond the original composition patent.
These claims are valuable but fragile, and they behave differently in an analysis. Their scope turns on the claimed indication and dosage regimen, their infringement usually runs through induced use rather than the sale of the molecule, and their validity is exposed to the same unexamined-grant uncertainty that marks Swiss national patents. A portfolio full of second-medical-use and formulation claims can look strong on paper and prove thin under scrutiny.
Our review reads each secondary family for what it actually blocks: which indication, which formulation, which dosing schedule, and for how long relative to the basic patent and any SPC. Where a secondary claim is the last line of defence for a mature product, we flag it for a hard validity look, and where the exposure runs the other way we scope a patent invalidation strategy against a competitor’s late-stage claim.
The Swiss Federal Patent Court in St. Gallen and litigation-readiness
A portfolio is only as strong as the forum that will enforce it, and Switzerland has a single, specialist one. Since 2012 the Swiss Federal Patent Court (Bundespatentgericht), seated in St. Gallen, has held exclusive first-instance jurisdiction over the validity and infringement of Swiss patents nationwide. Its judges combine legal and technical training, and its decisions are appealed directly to the Federal Supreme Court in Lausanne.
Because one court hears every patent dispute in the country, its case law is coherent and predictable in a way that fragmented national systems are not, which makes litigation risk easier to model across a portfolio. It also means that a Swiss enforcement action stands entirely apart from any UPC proceeding on the parallel EU rights, giving a patent owner a second, independent front and a defendant one more validity battle to fight.
We build every Basel portfolio analysis to be litigation-aware for this court: which patents are strong enough to assert in St. Gallen, which are exposed to a nullity counterclaim, and where an unexamined grant needs a prior-art foundation before it is ever put in front of a technically qualified judge.
The tri-national region: coordinating Swiss, German and French filings
Basel sits at Europe’s three-countries corner, where Switzerland, Germany and France meet, and its research footprint crosses all three borders. A single Basel innovation is often manufactured, trialled or sold across the tri-national region, which means the portfolio protecting it has to work in three different legal systems at once.
Here the UPC line reappears. Germany and France are core UPC members, so the EU-facing part of a Basel portfolio can now be litigated or centrally revoked at the Unified Patent Court, while the Swiss designation cannot. A coherent analysis therefore treats the same invention as two coordinated but distinct assets: a unitary or classically validated European right for the EU side, and a national Swiss-Liechtenstein right that answers only to St. Gallen.
That split drives real decisions about where to spend renewal budget, which markets justify SPC filings, and how to stage enforcement so an EU-wide UPC action and a Swiss national suit reinforce rather than undercut each other. We map the whole cross-border family so the strategy is deliberate, not an accident of where patents happened to be validated.
How we work with Basel counsel and in-house IP teams
Most Basel work reaches us in one of two postures: an in-house team preparing a licensing, financing or divestment decision that needs a defensible valuation of an estate, or counsel weighing whether a set of patents is strong enough to assert or acquire. Both start the same way, with the families, the products they protect, and the true expiry date of each exclusivity.
We work from the patents themselves, the IPI and Swissreg registers, SPC and paediatric-certificate records, Swissmedic approval histories and the published literature that Basel’s researchers generate in volume. The deliverable is a portfolio map and a written analysis that states plainly which assets carry commercial weight, which are unexamined and untested, where SPCs or second-medical-use claims extend the runway, and where the exposure justifies a validity search or an IP monetization play.
Basel runs on Central European Time and inside the European business day, so work coordinated with Swiss patent attorneys, St. Gallen litigation counsel and cross-border teams in Germany and France moves within a single cycle. The aim is an analysis your board or your court can act on, grounded in how the Swiss system actually works rather than in a UPC template that does not apply here.
IP Landscape & Resources in Basel
Key intellectual-property authorities and venues relevant to Basel:
- Swiss Federal Institute of Intellectual Property (IPI / IGE) — grants and administers Swiss national patents and SPCs and maintains the Swissreg register, without examining national patents for novelty or inventive step
- Swiss Federal Patent Court (Bundespatentgericht), St. Gallen — the single specialist court with exclusive first-instance jurisdiction over the validity and infringement of Swiss patents, with appeals to the Federal Supreme Court in Lausanne
- European Patent Office (EPO) — grants the European patents that must then be validated nationally in Switzerland and Liechtenstein, which sit outside the EU unitary patent and the Unified Patent Court
Request a Patent Portfolio Analysis Review in Basel
Request a Patent Portfolio Analysis Review in Basel
Send us your patent families, the products they protect and the markets that matter, and we will map exclusivity to expiry across your Swiss national rights, SPCs and second-medical-use claims. We confirm scope, cost and turnaround before any work begins.
Explore related PerspireIP services: Patent Portfolio Analysis · prior art & litigation search · patent invalidation · our Switzerland IP hub.
Frequently Asked Questions
Is a European patent automatically protected in Basel?
No. Switzerland is outside the EU, the unitary patent and the Unified Patent Court, so a European patent granted by the EPO must be validated nationally to take effect in Switzerland. That validation also covers Liechtenstein, because the two countries form a single unitary protection territory under their 1978 Patent Treaty.
Does the Swiss patent office examine patents for novelty?
Not under current practice. The IPI grants a Swiss national patent without examining it for novelty or inventive step, so the patent is granted without guarantee and can be invalidated later if challenged. From 1 January 2027 applicants will be able to request full substantive examination, which will change the validity profile of newer filings.
Why do SPCs matter so much in a Basel pharma portfolio?
Because they extend the most profitable years of exclusivity. A Swiss supplementary protection certificate can add up to five years of protection after the basic patent expires, plus a six-month paediatric extension since 2019, to offset the time lost to Swissmedic approval. Modelling each product’s SPC is essential to knowing when exclusivity truly ends.
Where would a Basel patent be litigated?
Before the Swiss Federal Patent Court in St. Gallen, which since 2012 has exclusive first-instance jurisdiction over the validity and infringement of Swiss patents nationwide. Its decisions are appealed to the Federal Supreme Court in Lausanne. This is entirely separate from any Unified Patent Court proceeding on parallel EU rights.
How do second-medical-use claims affect a portfolio’s value?
They can extend commercial exclusivity beyond the original compound patent by protecting a new therapeutic use of a known molecule, which is a mainstay of Basel lifecycle strategy. But their scope is narrow and their unexamined Swiss validity is untested, so a portfolio review has to read each one for what it actually blocks and how long it holds.
How does the tri-national Basel region complicate the analysis?
Basel sits where Switzerland, Germany and France meet, and Germany and France are core UPC members while Switzerland is not. The same invention therefore splits into a UPC-exposed EU right and an independent Swiss-Liechtenstein right that answers only to St. Gallen, so renewal, SPC and enforcement decisions must be coordinated across two different systems.